Meet
Megan Olsen

Megan Olsen supports clients in anticipating and navigating the evolving federal and state health policy environment.

In particular, she advises clients on their business and advocacy strategies related to legislative and regulatory developments. Megan has specific expertise in drug pricing policy, Medicaid, and health insurance markets and she contributes to the firm’s analysis of Medicaid managed care trends.

Prior to joining Avalere, Megan was a public policy fellow with Novo Nordisk, where she assessed the impact of public policy developments to shape and support the company’s advocacy priorities. Megan previously interned at Avalere Health in the Health Reform practice as well as with the New York State Department of Labor in the Research and Statistics Division.

Megan has an MPH in health policy from George Washington University’s Milken Institute School of Public Health and BA in economics and psychology from Saint Michael’s College.

Authored Content


Reforms to “eliminate rebates” could have varying impacts based on features of their design.

The Department of Health and Human Services is seeking public input on a variety of proposals related to drug costs, providing stakeholders with an unprecedented opportunity to shape the administration's drug pricing policies.

On March 6, Avalere experts came together to discuss the latest Medicaid developments.

Avalere experts discuss an evolving Medicaid program supported by a new administration and novel state approaches.

Capping Medicaid funding could also shift costs to Medicare

While 31 states and D.C. expanded Medicaid under the ACA, the future of expansion is uncertain.

New analysis from Avalere finds that 1.2 million individuals from non-expansion states could gain Medicaid coverage in 2017 should a newly elected governor decide to expand the program.